Pharmabcine Inc.

Seon Hwan Oh

Hyuk Jin Lee

Seon Young Lee

Do Yun Kim

Weon Sup Lee

Sang Soon Byun

Sang Ryeol Shim

Jae Bong Yoon

Jin San Yoo

Jong Geun Jeong

Nam Ye Kim

Sung Woo Kim

Young Ae Lee

In Sook Park

Sang Hoon Lee

Joong Kyu Kim

Eun Jin Lee

Jin Sang Yoo

Mi Ju Park

Jin Hee Choi

Jin Sook Lee

Bo Young Jeong

Ju Ryung Nam

Kyung Hee Nahm

Yeun Ju Kim

Sung-Woo Kim

Eun Hee Lee

Jinsang Yoo

Miju Park

Youngae Lee

Jinhee Choi

Hyuk Joon Lee

Ji Hye Jeong

Ju Ryoung Nam

Yeon Ju Kim

Boyoung Jeong

Kyoung Hee Nahm

Mi Ae Jeon

The present invention relates to a novel form of a dual-target antibody targeting VEGFR-2 and DLL4, a gene encoding the same, a recombinant expression vector including the gene, host cells transformed with the recombinant expression vector, a method of producing the dual-target antibody using the host cells, a pharmaceutical composition comprising the dual-target antibody.

Dual-target antibody targeting VEGFR-2 and DLL4 and pharmaceutical composition including same

Provided are an antibody specifically bound to c-Met (c-Met-specific antibody) or fragments thereof, and more specifically, a fully human antibody having high affinity and specificity to c-Met isolated from human Fv(ScFv) phage library, a polynucleotide encoding the antibody, a recombinant vector containing the polynucleotide, a cell transformed with the recombinant vector, and a method of producing the c-Met-specific antibody by culturing the cell, wherein the c-Met-specific antibody may effectively control activity of c-Met in vivo.

Human antibody specific to c-Met and preparation method thereof

Dual-target antibody targeting VEGFR-2 and DLL4, and pharmaceutical composition including same

Growing community of inventors

Daejeon, South Korea

Seon Hwan Oh